EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin

Mengjiao Hao, Zhuoji Guan, Zhikang Zhang, Haopeng Ai, Xing Peng, Huihao Zhou, Jun Xu, Qiong Gu

Molecular Therapy · 2023-10 · 31 (10) · 3015-3033

DOI: 10.1016/j.ymthe.2023.08.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2023-10. Verfasst von Mengjiao Hao und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Tea Research Institute, Guangdong Academy of Agricultural Science…. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province, Administration of Traditional Chinese Medicine of Jilin Province, State Key Laboratory of Phytochemistry and Plant Resources in West China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirfenidone and nintedanib are only anti-pulmonary fibrosis (PF) drugs approved by the FDA. However, they are not target specific, and unable to modify the disease status. Therefore, it is still desirable to discover more effective agents against PF. Vimentin (VIM) plays key roles in tissue regeneration and wound healing, but its molecular mechanism remains unknown. In this work, we demonstrated that atractylodinol (ATD) significantly inhibits TGF-β1-induced epithelial-mesenchymal transition and fibroblast-to-myofibroblast transition in vitro. ATD also reduces bleomycin-induced lung injury and fibrosis in mice models. Mechanistically, ATD inhibited TGF-β receptor I recycling by binding to VIM (KD = 454 nM) and inducing the formation of filamentous aggregates. In conclusion, we proved that ATD (derived from Atractylodes lancea) modified PF by targeting VIM and inhibiting the TGF-β/Smad signaling pathway. Therefore, VIM is a druggable target and ATD is a proper drug candidate against PF. We prove a novel VIM function that TGF-β receptor I recycling. These findings paved the way to develop new targeted therapeutics against PF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary FibrosisAnimalsMiceBleomycinEpithelial-Mesenchymal TransitionLungReceptor, Transforming Growth Factor-beta Type ITransforming Growth Factor beta1Vimentin

Stichwörter der Autor:innen

TGF-β receptorTGF-β/Smadatractylodinolpulmonary fibrosisvimentin

Substanzen

BleomycinReceptor, Transforming Growth Factor-beta Type ITransforming Growth Factor beta1Vimentin

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Tea Research Institute, Guangdong Academy of Agricultural Sciences, Guangdong Key Laboratory of Tea Resources Innovation & Utilization,…
  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China. Electronic address: xujun9@mail.sysu.edu.cn.
  • School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kun…

Förderung

  • Special Project for Research and Development in Key areas of Guangdong Province
  • Administration of Traditional Chinese Medicine of Jilin Province
  • State Key Laboratory of Phytochemistry and Plant Resources in West China

Zitieren

APA

Hao, M., Guan, Z., Zhang, Z., Ai, H., Peng, X., Zhou, H., Xu, J., & Gu, Q. (2023). Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin. Molecular Therapy, 31(10), 3015-3033. https://doi.org/10.1016/j.ymthe.2023.08.017

Vancouver

Hao M, Guan Z, Zhang Z, Ai H, Peng X, Zhou H, et al. Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin. Molecular Therapy. 2023;31(10):3015-3033. doi:10.1016/j.ymthe.2023.08.017

BibTeX
@article{Hao2023,
  author = {Hao, Mengjiao and Guan, Zhuoji and Zhang, Zhikang and Ai, Haopeng and Peng, Xing and Zhou, Huihao and Xu, Jun and Gu, Qiong},
  title = {Atractylodinol prevents pulmonary fibrosis through inhibiting TGF-β receptor 1 recycling by stabilizing vimentin},
  journal = {Molecular Therapy},
  year = {2023},
  volume = {31},
  number = {10},
  pages = {3015--3033},
  doi = {10.1016/j.ymthe.2023.08.017}
}
Kostenlos starten →